<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599907</url>
  </required_header>
  <id_info>
    <org_study_id>CB-CLP-001</org_study_id>
    <nct_id>NCT04599907</nct_id>
  </id_info>
  <brief_title>Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating</brief_title>
  <official_title>An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Candesant Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Candesant Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for&#xD;
      use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sahara Study is intended to evaluate the safety and effectiveness of the N-SWEAT Patch&#xD;
      for use in subjects with excessive axillary sweating, or primary focal axillary&#xD;
      hyperhidrosis.&#xD;
&#xD;
      Safety of the N-SWEAT Patch will be confirmed by assessing the occurrence of local skin&#xD;
      reactions, treatment-related adverse events (AEs) and Serious Adverse Events (SAEs).&#xD;
&#xD;
      Demonstration of effectiveness will be assessed by a significant improvement (reduction) in&#xD;
      Hyperhidrosis Disease Severity Score (HDSS) in subjects treated with the N-SWEAT Patch.&#xD;
      Secondary and additional endpoints based on complementary clinical instruments, including&#xD;
      Quality of Life Measures (QOL) and Gravimetric Sweat Production GSP), have been included to&#xD;
      further demonstrate performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the N-SWEAT Patch</measure>
    <time_frame>2 weeks</time_frame>
    <description>Occurrence of AEs and Skin reactions following patch treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in HDSS (Based on a 4-point scale)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Achievement of HDSS Score 1 or 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL (Based on a 5 point scale with 0=no improvement and 5=extreme improvement)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean improvement in QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% improvement in GSP (measured in mg/5min)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of treated subjects with at least 50% improvement in GSP from baseline to 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Primary Axillary Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Roll-In Cohort: N-SWEAT Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with N-SWEAT Patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Cohort: N-SWEAT Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with N-SWEAT Patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Cohort: Sham Patch</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will undergo identical procedure with an inactive sham device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Roll-In Cohort: Single Application of N-SWEAT Patch</intervention_name>
    <description>Single Application of N-SWEAT Patch in both axillae for 10 subjects</description>
    <arm_group_label>Roll-In Cohort: N-SWEAT Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Randomized Cohort: Single Application of N-SWEAT Patch</intervention_name>
    <description>Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group</description>
    <arm_group_label>Randomized Cohort: N-SWEAT Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Randomized Cohort: Single Application of Sham Patch</intervention_name>
    <description>Single Application of Sham Patch in both axillae for subjects randomized to the control group</description>
    <arm_group_label>Randomized Cohort: Sham Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. At least 22 years old at the time of consent.&#xD;
&#xD;
          3. Female or male, who experiences excessive sweating or has been diagnosed with primary&#xD;
             axillary focal hyperhidrosis and is in otherwise good general health&#xD;
&#xD;
          4. GSP &gt;50mg/5min in each axilla&#xD;
&#xD;
          5. Reports a score of HDSS score of 3 or 4&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Active skin disease, irritation, or abrasions at either axilla based&#xD;
&#xD;
          2. Subject's medical history is indicative of secondary or diffuse hyperhidrosis and/or&#xD;
             subject has a diagnosis of secondary or diffuse hyperhidrosis&#xD;
&#xD;
          3. GSP exceeds 300 mg/5min in either axilla&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Candesant Biomedical - Medical Monitor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CA Dermatology &amp; Clinical Research Inst</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AE Derm</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skincare Physicians</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services, Zoe Draelos, MD</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Your Health</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pariser Derm / Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016 Dec;308(10):743-749. Epub 2016 Oct 15.</citation>
    <PMID>27744497</PMID>
  </results_reference>
  <results_reference>
    <citation>Glaser DA, Coleman WP 3rd, Fan LK, Kaminer MS, Kilmer SL, Nossa R, Smith SR, O'Shaughnessy KF. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg. 2012 Feb;38(2):185-91. doi: 10.1111/j.1524-4725.2011.02250.x. Epub 2012 Jan 30.</citation>
    <PMID>22289389</PMID>
  </results_reference>
  <results_reference>
    <citation>Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding Patient Experience With Hyperhidrosis: A National Survey of 1,985 Patients. J Drugs Dermatol. 2018 Apr 1;17(4):392-396.</citation>
    <PMID>29601615</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin. 2014 Oct;32(4):467-76. doi: 10.1016/j.det.2014.06.004. Epub 2014 Jul 16. Review.</citation>
    <PMID>25152339</PMID>
  </results_reference>
  <results_reference>
    <citation>Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, Ahn S, Stolman LP; Multi-Specialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004 Aug;51(2):274-86. Review.</citation>
    <PMID>15280848</PMID>
  </results_reference>
  <results_reference>
    <citation>Stander M, Wallis LA. The emergency management and treatment of severe burns. Emerg Med Int. 2011;2011:161375. doi: 10.1155/2011/161375. Epub 2011 Sep 4.</citation>
    <PMID>22046536</PMID>
  </results_reference>
  <results_reference>
    <citation>Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004 Aug;51(2):241-8.</citation>
    <PMID>15280843</PMID>
  </results_reference>
  <results_reference>
    <citation>Wade R, Rice S, Llewellyn A, Moloney E, Jones-Diette J, Stoniute J, Wright K, Layton AM, Levell NJ, Stansby G, Craig D, Woolacott N. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. Health Technol Assess. 2017 Dec;21(80):1-280. doi: 10.3310/hta21800.</citation>
    <PMID>29271741</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilke K, Martin A, Terstegen L, Biel SS. A short history of sweat gland biology. Int J Cosmet Sci. 2007 Jun;29(3):169-79. doi: 10.1111/j.1467-2494.2007.00387.x.</citation>
    <PMID>18489347</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Excessive Axillary Sweating</keyword>
  <keyword>Primary Axillary Hyperhidrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

